Membrane-bound sn-1,2-diacylglycerols explain the dissociation of hepatic insulin resistance from hepatic steatosis in MTTP knockout mice

Microsomal triglyceride transfer protein (MTTP) deficiency results in a syndrome of hypolipidemia and accelerated NAFLD. Animal models of decreased hepatic MTTP activity have revealed an unexplained dissociation between hepatic steatosis and hepatic insulin resistance. Here, we performed comprehensive metabolic phenotyping of liver-specific MTTP knockout (L-Mttp−/−) mice and age-weight matched wild-type control mice. Young (10–12-week-old) L-Mttp−/− mice exhibited hepatic steatosis and increased DAG content; however, the increase in hepatic DAG content was partitioned to the lipid droplet and was not increased in the plasma membrane. Young L-Mttp−/− mice also manifested normal hepatic insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamps, no PKCε activation, and normal hepatic insulin signaling from the insulin receptor through AKT Ser/Thr kinase. In contrast, aged (10-month-old) L-Mttp−/− mice exhibited glucose intolerance and hepatic insulin resistance along with an increase in hepatic plasma membrane sn-1,2-DAG content and PKCε activation. Treatment with a functionally liver-targeted mitochondrial uncoupler protected the aged L-Mttp−/− mice against the development of hepatic steatosis, increased plasma membrane sn-1,2-DAG content, PKCε activation, and hepatic insulin resistance. Furthermore, increased hepatic insulin sensitivity in the aged controlled-release mitochondrial protonophore-treated L-Mttp−/− mice was not associated with any reductions in hepatic ceramide content. Taken together, these data demonstrate that differences in the intracellular compartmentation of sn-1,2-DAGs in the lipid droplet versus plasma membrane explains the dissociation of NAFLD/lipid-induced hepatic insulin resistance in young L-Mttp−/− mice as well as the development of lipid-induced hepatic insulin resistance in aged L-Mttp−/− mice.

[1]  G. Shulman,et al.  A Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance. , 2020, Cell metabolism.

[2]  Gina M. Butrico,et al.  Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates , 2019, Science Translational Medicine.

[3]  G. Shulman,et al.  Ectopic lipid deposition mediates insulin resistance in adipose specific 11β-hydroxysteroid dehydrogenase type 1 transgenic mice. , 2019, Metabolism: clinical and experimental.

[4]  G. Shulman,et al.  Mechanisms of Insulin Action and Insulin Resistance. , 2018, Physiological reviews.

[5]  M. Hussain,et al.  Lipid transfer proteins in the assembly of apoB-containing lipoproteins , 2018, Journal of Lipid Research.

[6]  G. Shulman,et al.  Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. , 2018, Cell metabolism.

[7]  R. Hegele,et al.  Lomitapide for the treatment of hypercholesterolemia , 2017, Expert opinion on pharmacotherapy.

[8]  H. Mao,et al.  Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis , 2017, Human molecular genetics.

[9]  K. Petersen,et al.  A controlled‐release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  M. Hussain,et al.  Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia , 2017, Critical reviews in clinical laboratory sciences.

[11]  Michael J. Marcel,et al.  Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. , 2016, The Journal of clinical investigation.

[12]  Jonathan C. Cohen,et al.  Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins* , 2016, The Journal of Biological Chemistry.

[13]  G. Shulman,et al.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. , 2016, The Journal of clinical investigation.

[14]  D. Rader,et al.  Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide* , 2015, The Journal of Biological Chemistry.

[15]  G. Shulman,et al.  Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats , 2015, Science.

[16]  P. Kovanen,et al.  Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia , 2014, Vascular health and risk management.

[17]  M. Hussain,et al.  Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice[S] , 2014, Journal of Lipid Research.

[18]  G. Shulman,et al.  Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. , 2013, Cell metabolism.

[19]  G. Shulman,et al.  Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. , 2013, American journal of physiology. Endocrinology and metabolism.

[20]  G. Shulman,et al.  CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance , 2013, Proceedings of the National Academy of Sciences.

[21]  Xianlin Han,et al.  Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease , 2011, Proceedings of the National Academy of Sciences.

[22]  R. de Cabo,et al.  Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. , 2011, Cell metabolism.

[23]  Avnish Patel,et al.  Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats , 2011, Clinical and experimental pharmacology & physiology.

[24]  G. Shulman,et al.  Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2 , 2011, Proceedings of the National Academy of Sciences.

[25]  M. Rizzo,et al.  New lipid modulating drugs: the role of microsomal transport protein inhibitors. , 2011, Current pharmaceutical design.

[26]  John T. Melchior,et al.  CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance[S] , 2010, Journal of Lipid Research.

[27]  K. Petersen,et al.  Lipid-induced insulin resistance: unravelling the mechanism , 2010, The Lancet.

[28]  P. Newsome,et al.  Pathogenesis of non-alcoholic fatty liver disease , 2009, QJM : monthly journal of the Association of Physicians.

[29]  M. Davidson Novel nonstatin strategies to lower low-density lipoprotein cholesterol , 2009, Current atherosclerosis reports.

[30]  H. Tilg,et al.  Inflammatory Mechanisms in the Regulation of Insulin Resistance , 2008, Molecular medicine.

[31]  G. Schonfeld,et al.  Fatty liver and insulin resistance: not always linked. , 2008, Transactions of the American Clinical and Climatological Association.

[32]  Richard E Gregg,et al.  Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[33]  G. Chang,et al.  CP-346086 Published, JLR Papers in Press, July 1, 2003. DOI 10.1194/jlr.M300094-JLR200 , 2003, Journal of Lipid Research.

[34]  M. Hussain,et al.  Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.R200014-JLR200 , 2003, Journal of Lipid Research.

[35]  G. Shulman,et al.  Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.

[36]  R. Donnelly,et al.  Tissue and Isoform-selective Activation of Protein Kinase C in Insulin-resistant Obese Zucker Rats – Effects of Feeding , 2022 .

[37]  J. Björkegren,et al.  Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. , 1999, The Journal of clinical investigation.

[38]  S. Young,et al.  A Gene-targeted Mouse Model for Familial Hypobetalipoproteinemia , 1998, The Journal of Biological Chemistry.

[39]  H. Jamil,et al.  An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. , 1998, Science.

[40]  D. Rader,et al.  Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. , 1992, Science.

[41]  Y. Nishizuka,et al.  Stereospecificity of diacylglycerol for stimulus-response coupling in platelets. , 1986, Biochemical and biophysical research communications.

[42]  R. Rando,et al.  The nature of protein kinase C activation by physically defined phospholipid vesicles and diacylglycerols. , 1985, The Journal of biological chemistry.

[43]  R. Rando,et al.  The stereospecific activation of protein kinase C. , 1984, Biochemical and biophysical research communications.

[44]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.